Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients

NCT06028633 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Advanced Non-squamous Non-small-cell Lung Cancer
Recurrent Non-Squamous Non-Small Cell Lung Cancer
Metastatic Non-squamous Non Small Cell Lung Cancer

Interventions

DRUG: pembrolizumab
DRUG: lenvatinib
DRUG: albumin-bound paclitaxel

Sponsor

Peking University First Hospital

Collaborators

[object Object]